Profile data is unavailable for this security.
About the company
Annexin Pharmaceuticals AB (publ) is a Sweden-based biotechnology company. Its main product is ANXV, a human recombinant protein Annexin A5, for emergency treatment of patients with cardiovascular disease with blood vessel damages and inflammation. ANXV has the ability to protect and repair the blood vessels, as well as counteract the inflammation. In addition, the Company has a comprehensive patent portfolio for the treatment of diseases that occur because of damage and blood vessel inflammation. The production process is patented. The Company maintains a cell line for manufacture of Annexin A5. The Company’s main shareholders are Mikael Loenn, Frostskog AB, Medirista AB and Colinex Capital AB.
- Revenue in SEK (TTM)0.00
- Net income in SEK-38.73m
- Incorporated2014
- Employees4.00
- LocationAnnexin Pharmaceuticals AB (publ)Kammakargatan 48STOCKHOLM 111 60SwedenSWE
- Phone+46 705755037
- Websitehttps://www.annexinpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chosa Oncology AB | 717.00k | -6.01m | 63.12m | -- | -- | 3.91 | -- | 88.03 | -0.0766 | -0.0766 | 0.0096 | 0.2044 | 0.0382 | -- | 0.8639 | -- | -32.00 | -55.65 | -35.30 | -67.69 | 643.24 | -- | -837.66 | -792.50 | -- | -49.05 | 0.00 | -- | -39.73 | -62.56 | 59.93 | -- | -- | -- |
| Lifecare ASA | 1.70m | -115.17m | 76.50m | 28.00 | -- | -- | -- | 45.04 | -2.48 | -2.48 | 0.0379 | -0.11 | 0.0168 | -- | 0.1582 | 55,272.73 | -115.30 | -52.64 | -194.19 | -61.98 | -- | -- | -6,864.75 | -277.39 | -- | -- | 1.17 | -- | -26.10 | 36.13 | -103.52 | -- | -- | -- |
| Opsy Holding AB | 4.13m | -18.69m | 82.53m | 7.00 | -- | 53.44 | -- | 19.99 | -20.83 | -20.83 | 0.6321 | 0.1216 | 0.294 | -- | 7.63 | 2,064,500.00 | -133.11 | -117.68 | -201.35 | -142.11 | 154.30 | -- | -452.72 | -- | -- | -216.84 | 0.463 | -- | -- | -- | -43.22 | -- | -- | -- |
| Spago Nanomedical AB (publ) | 1.05m | -28.49m | 83.03m | 8.00 | -- | 4.99 | -- | 79.07 | -0.058 | -0.058 | 0.0021 | 0.0251 | 0.0326 | -- | 10.14 | 80,769.23 | -88.56 | -24.44 | -104.41 | -25.71 | -- | -- | -2,713.71 | -3,325.49 | -- | -- | 0.00 | -- | 58.85 | 129.52 | 23.01 | -- | -- | -- |
| IDL Diagnostics AB (publ) | 52.19m | -39.31m | 87.54m | 22.00 | -- | 0.5851 | -- | 1.68 | -0.1706 | -0.1706 | 0.2266 | 0.6495 | 0.3263 | 6.59 | 5.26 | 2,372,364.00 | -24.58 | -29.04 | -26.98 | -31.14 | 21.53 | 1.70 | -75.32 | -157.60 | 3.29 | -- | 0.0843 | -- | 33.45 | 164.62 | 28.41 | -- | 18.85 | -- |
| Alligator Bioscience AB | 42.25m | -77.72m | 96.21m | 13.00 | -- | -- | -- | 2.28 | -2.16 | -2.16 | 0.6369 | -0.0592 | 0.5013 | -- | 9.35 | 938,822.30 | -92.22 | -97.96 | -- | -155.50 | -- | -- | -183.96 | -569.04 | -- | -- | 1.33 | -- | -0.5851 | 67.68 | 5.91 | -- | -- | -- |
| Active Biotech AB publ | 0.00 | -38.50m | 101.23m | 5.00 | -- | 13.23 | -- | -- | -0.0737 | -0.0737 | 0.00 | 0.0029 | 0.00 | -- | -- | 0.00 | -241.37 | -94.38 | -927.66 | -120.44 | -- | -- | -- | -3,355.24 | -- | -- | 0.0816 | -- | -- | -- | 13.98 | -- | -- | -- |
| Coegin Pharma AB | 0.00 | -20.64m | 105.48m | 3.00 | -- | 9.06 | -- | -- | -0.7859 | -0.7859 | 0.00 | 0.4681 | 0.00 | -- | -- | 0.00 | -85.07 | -133.34 | -91.51 | -179.59 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 15.00 | -- | -- | -- |
| Biosergen AB | 0.00 | -30.59m | 106.61m | 2.00 | -- | 5.26 | -- | -- | -13.74 | -13.74 | 0.00 | 8.63 | 0.00 | -- | -- | 0.00 | -152.65 | -- | -191.42 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 29.00 | -- | -- | -- |
| Exact Therapeutics AS | 0.00 | -67.23m | 110.74m | 12.00 | -- | 1.76 | -- | -- | -1.40 | -1.40 | 0.00 | 1.07 | 0.00 | -- | -- | 0.00 | -108.82 | -43.50 | -168.39 | -50.76 | -- | -- | -- | -- | -- | -20.18 | 0.0052 | -- | -- | -- | -8.27 | -- | 1.47 | -- |
| Annexin Pharmaceuticals AB (publ) | 0.00 | -38.73m | 112.24m | 4.00 | -- | 3.17 | -- | -- | -6.65 | -6.65 | 0.00 | 5.02 | 0.00 | -- | -- | 0.00 | -113.73 | -145.61 | -127.96 | -179.48 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.07 | -- | -- | -- |
| Glycorex Transplantation AB (publ) | 39.94m | -7.06m | 115.27m | 20.00 | -- | 3.23 | 48.99 | 2.89 | -0.0917 | -0.0917 | 0.5174 | 0.4719 | 0.7442 | 1.45 | 5.20 | 1,997,000.00 | -13.15 | -15.79 | -17.51 | -18.66 | 81.68 | 87.06 | -17.67 | -44.85 | 1.56 | -15.83 | 0.1599 | -- | 17.35 | -0.5296 | 63.97 | -- | -- | -- |
| Abera Bioscience AB | 0.00 | -1.45m | 118.30m | 5.00 | -- | 4.21 | -- | -- | -0.0872 | -0.0872 | 0.00 | 1.51 | 0.00 | -- | -- | 0.00 | -6.61 | -68.96 | -7.94 | -85.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 93.42 | -- | -- | -- |
| Alzinova AB | 205.00k | -26.88m | 118.34m | 5.00 | -- | 0.5785 | -- | 577.29 | -0.2846 | -0.2846 | 0.0022 | 1.23 | 0.0015 | -- | 0.3254 | 41,000.00 | -19.42 | -12.21 | -20.69 | -12.85 | -5,834.15 | -- | -13,114.15 | -21,390.81 | -- | -1,794.80 | 0.0062 | -- | -88.89 | -- | -24.71 | -- | 19.48 | -- |
| Biovica International AB | 9.86m | -76.47m | 122.23m | 24.00 | -- | 1.05 | -- | 12.39 | -0.6375 | -0.6375 | 0.0684 | 0.4241 | 0.0799 | 12.71 | 4.46 | 365,333.30 | -61.92 | -58.22 | -70.41 | -66.49 | -171.53 | -462.09 | -775.22 | -1,804.16 | 8.11 | -- | 0.0239 | -- | 18.23 | 38.83 | 29.80 | -- | -47.26 | -- |
| SoftOx Solutions AS | 12.65m | -2.79m | 136.06m | 5.00 | -- | 1.35 | 181.44 | 10.75 | -0.001 | -0.001 | 0.0065 | 0.0445 | 0.123 | -- | 30.13 | 2,717,798.00 | -2.72 | -50.91 | -3.22 | -67.07 | -- | -- | -22.07 | -644.92 | 1.16 | -3.92 | 0.1212 | -- | 13.38 | 14.06 | -8.86 | -- | -- | -- |
Data as of Feb 06 2026. Currency figures normalised to Annexin Pharmaceuticals AB (publ)'s reporting currency: Swedish Krona SEK
0.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| FCG Fonder ABas of 31 Mar 2025 | 770.00 | 0.01% |
Data from 30 Dec 2025 - 30 Dec 2025Source: FactSet Research Systems Inc.
